<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796352</url>
  </required_header>
  <id_info>
    <org_study_id>15-114</org_study_id>
    <nct_id>NCT02796352</nct_id>
  </id_info>
  <brief_title>A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study</brief_title>
  <official_title>A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmad Tarhini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prometheus Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients with advanced stage III or stage IV melanoma not adequately&#xD;
      treated by surgery who have progressed after treatment with nivolumab or pembrolizumab. The&#xD;
      purpose of this study is to see if giving high dose interleukin-2 (IL-2) after progression on&#xD;
      nivolumab or pembrolizumab is effective in treating metastatic melanoma. This study is also&#xD;
      being done to look at the severity of side effects of IL-2 in patients.&#xD;
&#xD;
      IL-2 is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II study of high dose bolus interleukin-2 (HD IL2) in patients with advanced&#xD;
      inoperable stage III or stage IV melanoma who have prior anti-PD1 immunotherapy.&#xD;
&#xD;
      Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is&#xD;
      given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest&#xD;
      period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second&#xD;
      cycle).&#xD;
&#xD;
      The planned treatment consists of 3 courses (6 cycles) of HD IL-2. Response assessment will&#xD;
      occur at the end of each course of therapy and patients without evidence of disease&#xD;
      progression (Response Evaluation Criteria in Solid Tumors, RECIST, version 1.1) or limiting&#xD;
      toxicities will be offered additional courses of treatment of HD IL2 for a maximum of 3&#xD;
      courses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual.&#xD;
  </why_stopped>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">February 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 15 months for accrual, plus 6 months of intervention for last subject enrolled (21 months)</time_frame>
    <description>Percentage of complete responses (CR) plus partial responses (PR), based upon Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 15 months for accrual, plus 6 months of intervention for last subject enrolled, plus 5 years of follow-up (6 years, 9 months)</time_frame>
    <description>Number of months of survival without disease progression from start of protocol therapy until objective tumor progression or death, per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 15 months for accrual, plus 6 months of intervention for last subject enrolled, plus 5 years of follow-up (6 years, 9 months)</time_frame>
    <description>Number of months from start of protocol therapy until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HD IL2 Levels</measure>
    <time_frame>Up to 21 months</time_frame>
    <description>Levels of HD IL2 biomarker in the blood of patients that received at least course 1 of therapy, and have had their disease re-evaluated will be considered evaluable for response per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) version 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>High dose bolus interleukin-2 (HD IL2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose bolus interleukin-2 (HD IL2)</intervention_name>
    <description>Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).&#xD;
The planned treatment consists of 3 courses (6 cycles) of HD IL-2.</description>
    <arm_group_label>High dose bolus interleukin-2 (HD IL2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed metastatic melanoma. This&#xD;
             includes American Joint Committee on Cancer (AJCC) stage IV or advanced/inoperable&#xD;
             stage III. This also includes patients with a history of lower stage melanoma and&#xD;
             subsequent recurrent metastatic disease that is either locally/regionally&#xD;
             advanced/inoperable disease or distant metastases.&#xD;
&#xD;
          -  Patients must have measurable disease, according to RECIST version 1.1&#xD;
&#xD;
          -  Patients must be free of active brain metastasis by contrast-enhanced CT/MRI scans&#xD;
             within 4 weeks prior to enrollment. If known to have prior brain metastases, these&#xD;
             must have been adequately managed with standard of care radiation therapy,&#xD;
             stereotactic radiosurgery or surgery prior to registration on the study.&#xD;
&#xD;
          -  A patient must have previously received anti-PD1 immunotherapy (nivolumab or&#xD;
             pembrolizumab) and later experienced disease progression, within 3 months of&#xD;
             registration on this study.&#xD;
&#xD;
          -  Patients must not have received systemic therapy or radiotherapy within the preceding&#xD;
             3 weeks. Patients must have recovered from adverse events from previous therapy by the&#xD;
             time registration.&#xD;
&#xD;
          -  Patients must be at least 4 weeks from major surgery and have fully recovered from any&#xD;
             effects of surgery, and be free of significant detectable infection prior to&#xD;
             registration.&#xD;
&#xD;
          -  For patients who have received prior anti-CTLA4 monoclonal antibody therapy&#xD;
             (ipilimumab or tremelimumab), there is a risk of bowel perforation with IL-2 therapy.&#xD;
             Therefore, for these patients if they have a history of colitis or diarrhea during&#xD;
             anti-CTLA4 monoclonal antibody therapy, it is recommended that they have a formal&#xD;
             evaluation by a gastroenterologist and a colonoscopy/endoscopy should be considered to&#xD;
             demonstrate the absence of active bowel inflammation before initiating IL-2 therapy on&#xD;
             this protocol.&#xD;
&#xD;
          -  Life expectancy of greater than 3 months in the opinion of the investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky &gt;/=70%)&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined in the clinical trial&#xD;
             protocol.&#xD;
&#xD;
          -  Patients on full-dose anticoagulants (e.g., warfarin) with prothrombin time (PT)/&#xD;
             international normalized ratio (INR) &gt;1.5 are eligible provided that both of the&#xD;
             following criteria are met: (a) The patient has an in-range INR (usually between 2 and&#xD;
             3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight&#xD;
             heparin. (b) The patient has no active bleeding or pathological condition that carries&#xD;
             a high risk of bleeding (e.g., tumor involving major vessels or known varices).&#xD;
&#xD;
          -  Pulmonary: forced expiratory volume at one second (FEV1) &gt; 2.0 liters or &gt; 75% of&#xD;
             predicted for height and age. Pulmonary function tests (PFTs) are required for&#xD;
             patients over 50 years old or with significant pulmonary or smoking history.&#xD;
&#xD;
          -  Cardiac: No evidence of congestive heart failure, symptoms of coronary artery disease,&#xD;
             myocardial infarction less than 6 months prior to entry, serious cardiac arrhythmias,&#xD;
             or unstable angina. Patients who are over 40 years old or have had previous myocardial&#xD;
             infarction greater than 6 months prior to study entry or have significant cardiac&#xD;
             family history (CAD or serious arrhythmias) will be required to have a negative or low&#xD;
             probability cardiac stress test (for example, thallium stress test, stress multigated&#xD;
             acquisition (MUGA), stress echo or exercise stress test) for cardiac ischemia within 8&#xD;
             weeks prior to registration.&#xD;
&#xD;
          -  Central Nervous System (CNS): No history of cerebrovascular accident or transient&#xD;
             ischemic attacks within the past 6 months from registration.&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for at least 6 months after completion of&#xD;
             study therapy. Should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study, she should inform her treating physician immediately.&#xD;
&#xD;
          -  Women should not be lactating and, if of childbearing age, should have a negative&#xD;
             pregnancy test (b-HCG test; serum or urine, minimum sensitivity 25 IU/L or equivalent&#xD;
             units of b-HCG) within two week of registration in the study.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had systemic therapy for melanoma or radiotherapy within 3 weeks&#xD;
             prior to registering on the study or those who have not recovered from adverse events&#xD;
             due to agents administered more than 3 weeks earlier. Patients with a history of&#xD;
             endocrinopathies (e.g. hypothyroidism, adrenal insufficiency, hypopituitarism) are&#xD;
             eligible if they are stable on hormone replacement therapy.&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents.&#xD;
&#xD;
          -  Patients with active brain metastases should be excluded from this clinical trial&#xD;
             except as noted above.&#xD;
&#xD;
          -  Patients with clinically significant cardiovascular or cerebrovascular disease:&#xD;
&#xD;
               1. history of cerebrovascular accident or transient ischemic attack within past 6&#xD;
                  months from registration.&#xD;
&#xD;
               2. myocardial infarction, coronary artery bypass grafting (CABG) or unstable angina&#xD;
                  within the past 6 Months from registration.&#xD;
&#xD;
               3. New York Heart Association grade III or greater congestive heart failure, serious&#xD;
                  cardiac arrhythmia requiring medication, unstable angina pectoris within past 6&#xD;
                  months from registration.&#xD;
&#xD;
               4. clinically significant peripheral vascular disease within past 6 months from&#xD;
                  registration.&#xD;
&#xD;
          -  PT INR &gt;1.5 unless the patient is on full-dose warfarin.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Patients who have other current malignancies are not eligible. Patients with other&#xD;
             malignancies are eligible if they have been continuously disease free for &gt; 2 years&#xD;
             prior to the time of registration. Patients with prior history at any time of any in&#xD;
             situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ,&#xD;
             atypical melanocytic hyperplasia or melanoma in situ are eligible. Patients with prior&#xD;
             history of basal or squamous skin cancer are eligible. Patients who have had multiple&#xD;
             primary melanomas are eligible.&#xD;
&#xD;
          -  Patients must not have autoimmune disorders or conditions of immunosuppression that&#xD;
             require current ongoing treatment with systemic corticosteroids (or other systemic&#xD;
             immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or&#xD;
             continuous use of topical steroid creams or ointments or ophthalmologic steroids or&#xD;
             steroid inhalers. If a patient had been taking steroids, at least 2 weeks must have&#xD;
             passed since the last dose. Patients stable on physiologic replacement doses of&#xD;
             steroids or other forms of hormone replacement therapy are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Tarhini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center- Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <results_first_submitted>February 19, 2018</results_first_submitted>
  <results_first_submitted_qc>March 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2018</results_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ahmad Tarhini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT02796352/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Bolus Interleukin-2 (HD IL2)</title>
          <description>High dose bolus interleukin-2 (HD IL2): Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).&#xD;
The planned treatment consists of 3 courses (6 cycles) of HD IL-2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Bolus Interleukin-2 (HD IL2)</title>
          <description>High dose bolus interleukin-2 (HD IL2): Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).&#xD;
The planned treatment consists of 3 courses (6 cycles) of HD IL-2.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="63" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Percentage of complete responses (CR) plus partial responses (PR), based upon Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1</description>
        <time_frame>Up to 15 months for accrual, plus 6 months of intervention for last subject enrolled (21 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Bolus Interleukin-2 (HD IL2)</title>
            <description>High dose bolus interleukin-2 (HD IL2): Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).&#xD;
The planned treatment consists of 3 courses (6 cycles) of HD IL-2.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Percentage of complete responses (CR) plus partial responses (PR), based upon Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Number of months of survival without disease progression from start of protocol therapy until objective tumor progression or death, per RECIST v1.1</description>
        <time_frame>Up to 15 months for accrual, plus 6 months of intervention for last subject enrolled, plus 5 years of follow-up (6 years, 9 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Bolus Interleukin-2 (HD IL2)</title>
            <description>High dose bolus interleukin-2 (HD IL2): Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).&#xD;
The planned treatment consists of 3 courses (6 cycles) of HD IL-2.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Number of months of survival without disease progression from start of protocol therapy until objective tumor progression or death, per RECIST v1.1</description>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Number of months from start of protocol therapy until death from any cause.</description>
        <time_frame>Up to 15 months for accrual, plus 6 months of intervention for last subject enrolled, plus 5 years of follow-up (6 years, 9 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Bolus Interleukin-2 (HD IL2)</title>
            <description>High dose bolus interleukin-2 (HD IL2): Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).&#xD;
The planned treatment consists of 3 courses (6 cycles) of HD IL-2.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Number of months from start of protocol therapy until death from any cause.</description>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HD IL2 Levels</title>
        <description>Levels of HD IL2 biomarker in the blood of patients that received at least course 1 of therapy, and have had their disease re-evaluated will be considered evaluable for response per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) version 1.1</description>
        <time_frame>Up to 21 months</time_frame>
        <population>No data displayed because data were not collected for this Outcome Measure, thus zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Bolus Interleukin-2 (HD IL2)</title>
            <description>High dose bolus interleukin-2 (HD IL2): Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).&#xD;
The planned treatment consists of 3 courses (6 cycles) of HD IL-2.</description>
          </group>
        </group_list>
        <measure>
          <title>HD IL2 Levels</title>
          <description>Levels of HD IL2 biomarker in the blood of patients that received at least course 1 of therapy, and have had their disease re-evaluated will be considered evaluable for response per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) version 1.1</description>
          <population>No data displayed because data were not collected for this Outcome Measure, thus zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study entry until end of treatment (4 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Bolus Interleukin-2 (HD IL2)</title>
          <description>High dose bolus interleukin-2 (HD IL2): Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).&#xD;
The planned treatment consists of 3 courses (6 cycles) of HD IL-2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Stadterman, Regulatory Supervisor</name_or_title>
      <organization>University of Pittsburgh Cancer Institute</organization>
      <phone>(412) 647-5554</phone>
      <email>stadtermanbm@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

